Aberdeen Group’s Hemab Therapeutics COAG Stock Holding History

Aberdeen Group’s Portfolio COAG Stock Details COAG Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q3	–	Sell	-52,117	Closed	-$1.91M	–	1053
2026 Q2	$1.91M	Buy	+52,117	New	+$1.44M	﹤0.01%	780

Other funds holding COAG

Fidelity Investments Boston, Massachusetts $2.32T AUM 44.66% 1-Year Est. Return

Capital International Investors Los Angeles, California $483B AUM 27.72% 1-Year Est. Return

Siren LLC Greenwich, Connecticut $4.23B AUM 121.47% 1-Year Est. Return

JP Morgan Chase New York $1.84T AUM 33.86% 1-Year Est. Return

State Street Boston, Massachusetts $3.44T AUM 36.12% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return

UBS Group Zurich, Switzerland $765B AUM 28.39% 1-Year Est. Return

Ensign Peak Advisors Salt Lake City, Utah $60.6B AUM 33.98% 1-Year Est. Return

Renaissance Technologies New York $73.4B AUM 32.8% 1-Year Est. Return

Bank of New York Mellon New York $608B AUM 32.77% 1-Year Est. Return

Aberdeen Group's COAG Position: Q3 2026 in Review

Aberdeen Group sold out of Hemab Therapeutics (COAG) in Q3 2026, closing a stake of 52,117 shares — an estimated $1.91M sold.

Aberdeen Group first reported a position in COAG in Q2 2026 and held it in 1 quarter. The position peaked at $1.91M in Q2 2026. 31 funds tracked by Wall St. Rank hold COAG as of Q3 2026.

Aberdeen Group reported no remaining Hemab Therapeutics position as of Q3 2026 after selling out during the quarter.
Aberdeen Group sold 52,117 Hemab Therapeutics shares in Q3 2026, an estimated $1.91M.
Aberdeen Group first reported a position in Hemab Therapeutics in Q2 2026 and held it in 1 quarter.
Aberdeen Group's Hemab Therapeutics position peaked at $1.91M in Q2 2026.
31 funds tracked by Wall St. Rank held Hemab Therapeutics as of Q3 2026.

Based on Aberdeen Group's 13F filing for Q3 2026, filed 6 Nov 2026.